Skip to content

Clinical study for Motherwort injection in the treatment of residual fetal membranes after vaginal delivery (defective uterine involution)

Clinical study for Motherwort injection in the treatment of residual fetal membranes after vaginal delivery (defective uterine involution)

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800019664
Enrollment
Unknown
Registered
2018-11-21
Start date
2017-08-01
Completion date
Unknown
Last updated
2018-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

residual fetal membranes after vaginal delivery (defective uterine involution)

Interventions

Group 1:Postpartum basic treatment (oxytocin 20U/day + antibiotics for 3 consecutive days
oral administration of Fukang granules or maternal granules after discharge for 7 days), plus motherwort injection 2ml/time, 2 times/day, For 5 consecutive days.
Group 2:Basic treatment only

Sponsors

West China Second Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: (1) vaginal delivery; (2) Doctors or postpartum B-ultrasound examination, there are remnants of membranes, uterine involution, uterine effusion and other patients; (3) postpartum vaginal bleeding is more than normal menstrual volume; (4) agree to participate in the trial and sign informed consent.

Exclusion criteria

Exclusion criteria: (1) various placental factors such as placenta previa, uterine fibroids and tumors; (2) severe allergies and allergies to motherwort preparations; (3) acute inflammation of the reproductive organs; (4) Those with primary diseases such as severe cardiovascular, liver, kidney and hematopoietic system; (5) Psychiatric patients; (6) Patients who do not cooperate and are unwilling to sign informed consent; (7) The doctor thinks it is not suitable for inclusion in the researcher.

Design outcomes

Primary

MeasureTime frame
Lochia;Three diameter line of uterus;Residual membrane area;Infection-related factor;The rate of curettage after incomplete fetal membranes;Hemorrhagic recurrence rate;Incidence of infection;

Secondary

MeasureTime frame
Combined use of other hemostasis drugs;Postpartum temperature changes;Time of hospitalization;

Countries

China

Contacts

Public ContactLiu Xinghui

West China Second Hospital of Sichuan University

328541321@qq.com+86 18612599317

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026